Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.
This paper follows on from Part 1 of my review of bromodeoxyuridine published earlier this year (Dolbeare, 1995).
Dolbeare
F
F
Biology and Biotechnology Program, Lawrence Livermore National Laboratory, University of California 94551-9900, USA.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use / Q000633:toxicity; D001973:Bromodeoxyuridine / Q000627:therapeutic use / Q000633:toxicity; D002273:Carcinogens / Q000633:toxicity*; D006651:Histocytochemistry; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D002273:Carcinogens; D001973:Bromodeoxyuridine